WallStreetZenWallStreetZen

NASDAQ: IGMS
Igm Biosciences Inc Stock

$9.27+0.59 (+6.8%)
Updated Mar 27, 2024
IGMS Price
$9.27
Fair Value Price
$12.62
Market Cap
$544.95M
52 Week Low
$3.81
52 Week High
$17.78
P/E
-1.97x
P/B
2.68x
P/S
204.09x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.13M
Earnings
-$246.42M
Gross Margin
100%
Operating Margin
-11,537%
Profit Margin
-11,568.8%
Debt to Equity
1.08
Operating Cash Flow
-$192M
Beta
1.37
Next Earnings
Mar 28, 2024
Ex-Dividend
N/A
Next Dividend
N/A

IGMS Overview

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how IGMS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

IGMS ($9.27) is undervalued by 26.54% relative to our estimate of its Fair Value price of $12.62 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
IGMS ($9.27) is significantly undervalued by 26.54% relative to our estimate of its Fair Value price of $12.62 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
IGMS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IGMS due diligence checks available for Premium users.

Be the first to know about important IGMS news, forecast changes, insider trades & much more!

IGMS News

Valuation

IGMS fair value

Fair Value of IGMS stock based on Discounted Cash Flow (DCF)
Price
$9.27
Fair Value
$12.62
Undervalued by
26.54%
IGMS ($9.27) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IGMS ($9.27) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IGMS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

IGMS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.97x
Industry
14.3x
Market
44.45x

IGMS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.68x
Industry
6.2x
IGMS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

IGMS's financial health

Profit margin

Revenue
$651.0k
Net Income
-$60.7M
Profit Margin
-9,323.3%
IGMS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
IGMS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$423.4M
Liabilities
$220.2M
Debt to equity
1.08
IGMS's short-term assets ($347.60M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IGMS's short-term assets ($347.60M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IGMS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IGMS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$48.0M
Investing
-$14.7M
Financing
$402.0k
IGMS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

IGMS vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
IGMS$544.95M+6.80%-1.97x2.68x
MRSN$544.65M+4.42%-3.03x14.76x
NKTX$547.78M+12.31%-4.62x2.00x
BMEA$548.44M+2.74%-4.59x2.75x
LXRX$539.26M+10.61%-2.74x5.79x

Igm Biosciences Stock FAQ

What is Igm Biosciences's quote symbol?

(NASDAQ: IGMS) Igm Biosciences trades on the NASDAQ under the ticker symbol IGMS. Igm Biosciences stock quotes can also be displayed as NASDAQ: IGMS.

If you're new to stock investing, here's how to buy Igm Biosciences stock.

What is the 52 week high and low for Igm Biosciences (NASDAQ: IGMS)?

(NASDAQ: IGMS) Igm Biosciences's 52-week high was $17.78, and its 52-week low was $3.81. It is currently -47.86% from its 52-week high and 143.31% from its 52-week low.

How much is Igm Biosciences stock worth today?

(NASDAQ: IGMS) Igm Biosciences currently has 58,786,588 outstanding shares. With Igm Biosciences stock trading at $9.27 per share, the total value of Igm Biosciences stock (market capitalization) is $544.95M.

Igm Biosciences stock was originally listed at a price of $24.30 in Sep 18, 2019. If you had invested in Igm Biosciences stock at $24.30, your return over the last 4 years would have been -61.85%, for an annualized return of -21.41% (not including any dividends or dividend reinvestments).

How much is Igm Biosciences's stock price per share?

(NASDAQ: IGMS) Igm Biosciences stock price per share is $9.27 today (as of Mar 27, 2024).

What is Igm Biosciences's Market Cap?

(NASDAQ: IGMS) Igm Biosciences's market cap is $544.95M, as of Mar 28, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Igm Biosciences's market cap is calculated by multiplying IGMS's current stock price of $9.27 by IGMS's total outstanding shares of 58,786,588.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.